NASDAQ:IMMY - Imprimis Pharmaceuticals Stock Price, Price Target & More

$2.24 +0.02 (+0.90 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$2.24
Today's Range$2.20 - $2.25
52-Week Range$1.35 - $4.57
Volume89,563 shs
Average Volume420,301 shs
Market Capitalization$45.45 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.28

About Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive IMMY News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMMY
CUSIPN/A
Phone858-704-4040

Debt

Debt-to-Equity Ratio5.64%
Current Ratio1.53%
Quick Ratio1.14%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.77 million
Price / Sales1.74
Cash FlowN/A
Price / CashN/A
Book Value$0.13 per share
Price / Book17.23

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,980,000.00
Net Margins-44.76%
Return on Equity-248.39%
Return on Assets-46.28%

Miscellaneous

Employees128
Outstanding Shares20,850,000

How to Become a New Pot Stock Millionaire

Imprimis Pharmaceuticals (NASDAQ:IMMY) Frequently Asked Questions

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals (NASDAQ:IMMY) posted its earnings results on Thursday, March, 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter. The specialty pharmaceutical company had revenue of $7.34 million for the quarter. Imprimis Pharmaceuticals had a negative net margin of 44.76% and a negative return on equity of 248.39%. View Imprimis Pharmaceuticals' Earnings History.

When is Imprimis Pharmaceuticals' next earnings date?

Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Imprimis Pharmaceuticals.

Who are some of Imprimis Pharmaceuticals' key competitors?

Who are Imprimis Pharmaceuticals' key executives?

Imprimis Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark L. Baum, Founder, CEO & Director (Age 45)
  • Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 36)
  • Mr. John P. Saharek MBA, Chief Commercial Officer (Age 58)
  • Mr. David Moufarrège, VP of Technology
  • Mr. Pramod Sharma Ph.D., VP of Quality

Has Imprimis Pharmaceuticals been receiving favorable news coverage?

Media coverage about IMMY stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a news sentiment score of 0.16 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 47.44 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Imprimis Pharmaceuticals?

Shares of IMMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Imprimis Pharmaceuticals' stock price today?

One share of IMMY stock can currently be purchased for approximately $2.24.

How big of a company is Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals has a market capitalization of $45.45 million and generates $26.77 million in revenue each year. Imprimis Pharmaceuticals employs 128 workers across the globe.

How can I contact Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals' mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-704-4040 or via email at [email protected]


MarketBeat Community Rating for Imprimis Pharmaceuticals (IMMY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Imprimis Pharmaceuticals (NASDAQ:IMMY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/ABuyBuyBuy
Consensus Rating Score: N/A3.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$5.00$5.00$5.00
Price Target Upside: N/A101.61% upside101.61% upside101.61% upside

Imprimis Pharmaceuticals (NASDAQ:IMMY) Consensus Price Target History

Price Target History for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals (NASDAQ:IMMY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017Rodman & RenshawReiterated RatingBuy$5.00HighView Rating Details
11/28/2016HC WainwrightInitiated CoverageBuy$5.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Imprimis Pharmaceuticals (NASDAQ:IMMY) Earnings History and Estimates Chart

Earnings by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals (NASDAQ IMMY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018N/AView Earnings Details
3/8/2018Q4 2017($0.13)$7.34 millionViewN/AView Earnings Details
11/14/2017Q3 2017($0.28)$6.48 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.23)$0.06$6.86 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.19)($0.26)$6.50 million$6.10 millionViewN/AView Earnings Details
3/21/2017Q4 2016($0.28)($0.44)$5.50 million$5.79 millionViewN/AView Earnings Details
11/14/2016Q316($0.24)($0.29)$2.70 million$4.90 millionViewN/AView Earnings Details
8/15/2016Q216($0.35)$4.53 million$4.90 millionViewListenView Earnings Details
5/12/2016Q116($0.27)($0.43)$3.24 million$4.40 millionViewListenView Earnings Details
3/23/2016Q415($0.26)($0.53)$3.52 million$3.50 millionViewListenView Earnings Details
11/12/2015Q3 2015($0.43)($0.41)$2.68 millionViewN/AView Earnings Details
8/12/2015Q215($0.33)($0.39)$2.13 million$2.00 millionViewListenView Earnings Details
5/13/2015Q115($0.25)($0.33)$1.55 million$16.00 millionViewN/AView Earnings Details
3/12/2015Q414($0.25)($0.30)$0.68 million$0.55 millionViewN/AView Earnings Details
11/12/2014Q3 2014($0.27)$0.44 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.28)$0.67 millionViewN/AView Earnings Details
5/15/2014Q1 2014($0.26)ViewN/AView Earnings Details
3/28/2014Q4 2013($0.21)ViewN/AView Earnings Details
11/6/2013Q3 2013($0.23)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.25)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.19)ViewN/AView Earnings Details
11/8/2010Q3 2010($1.20)($1.88)ViewN/AView Earnings Details
8/12/2010Q2 2010($1.20)($1.20)ViewN/AView Earnings Details
5/13/2010Q1 2010($2.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Imprimis Pharmaceuticals (NASDAQ:IMMY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Imprimis Pharmaceuticals (NASDAQ IMMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.55%
Institutional Ownership Percentage: 10.98%
Insider Trading History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Institutional Ownership by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals (NASDAQ IMMY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/17/2017Robert J KammerDirectorSell10,000$3.05$30,500.001,059,827View SEC Filing  
12/19/2016Andrew R BollCFOBuy39,000$1.79$69,810.0054,000View SEC Filing  
12/19/2016Mark L BaumCEOBuy156,000$1.79$279,240.00325,835View SEC Filing  
12/19/2016Richard L Md LindstromDirectorBuy100,000$1.79$179,000.00100,000View SEC Filing  
3/11/2016Opaleye Management Inc.Major ShareholderBuy45,000$3.65$164,250.00View SEC Filing  
6/30/2015Opaleye Management Inc.Major ShareholderBuy35,000$7.90$276,500.00View SEC Filing  
5/19/2015Donald Paul MiloniMajor ShareholderSell410,000$8.00$3,280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Imprimis Pharmaceuticals (NASDAQ IMMY) News Headlines

Source:
DateHeadline
Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?
finance.yahoo.com - April 20 at 4:36 PM
Imprimis Pharmaceuticals (IMMY) Stock Rating Upgraded by Zacks Investment ResearchImprimis Pharmaceuticals (IMMY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:48 PM
Imprimis Pharmaceuticals (IMMY) Upgraded at ValuEngineImprimis Pharmaceuticals (IMMY) Upgraded at ValuEngine
www.americanbankingnews.com - April 18 at 1:24 PM
Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical MeetingImprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
finance.yahoo.com - April 10 at 9:45 AM
Imprimis Pharma (IMMY) Secures Composition Patent for Non-Opioid Conscious Sedation FormulationImprimis Pharma (IMMY) Secures Composition Patent for Non-Opioid Conscious Sedation Formulation
www.streetinsider.com - March 30 at 9:25 AM
Imprimis Spikes On New Composition Patent For Non-Opioid SedativeImprimis Spikes On New Composition Patent For Non-Opioid Sedative
www.msn.com - March 27 at 9:45 AM
Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation FormulationImprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
finance.yahoo.com - March 27 at 9:45 AM
Imprimis Pharmaceuticals (IMMY) Stock Rating Upgraded by ValuEngineImprimis Pharmaceuticals (IMMY) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 5:24 PM
Imprimis Pharmaceuticals (IMMY) Presents At 30th Annual ROTH Conference - SlideshowImprimis Pharmaceuticals (IMMY) Presents At 30th Annual ROTH Conference - Slideshow
seekingalpha.com - March 14 at 5:50 PM
Imprimis Pharmaceuticals, Inc. to Host Earnings CallImprimis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 5:29 PM
Imprimis Pharmaceuticals Announces Fourth Quarter 2017 ResultsImprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
finance.yahoo.com - March 8 at 5:29 PM
Wired News – Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic MedicationsWired News – Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications
finance.yahoo.com - March 8 at 9:40 AM
Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018
finance.yahoo.com - March 7 at 9:28 AM
Imprimis Pharmaceuticals (IMMY) Scheduled to Post Earnings on ThursdayImprimis Pharmaceuticals (IMMY) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 1 at 1:46 AM
Should You Be Content With Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Earnings Growth?Should You Be Content With Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Earnings Growth?
finance.yahoo.com - February 28 at 5:06 PM
Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. ESTImprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST
finance.yahoo.com - February 15 at 8:40 AM
Imprimis Pharmaceuticals (IMMY) and Ardelyx (ARDX) Head-To-Head ContrastImprimis Pharmaceuticals (IMMY) and Ardelyx (ARDX) Head-To-Head Contrast
www.americanbankingnews.com - January 31 at 9:44 AM
Today’s Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis PharmaceuticalsToday’s Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals
finance.yahoo.com - January 31 at 9:32 AM
Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?
finance.yahoo.com - January 31 at 9:32 AM
Imprimis Pharma (IMMY) Says Its Making Available Two Glaucoma Drugs on FDAs Drug Shortage ListImprimis Pharma (IMMY) Says It's Making Available Two Glaucoma Drugs on FDA's Drug Shortage List
www.streetinsider.com - January 30 at 4:22 PM
Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDAs Drug Shortage ListImprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List
finance.yahoo.com - January 30 at 9:40 AM
Blog Exposure - Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing FacilityBlog Exposure - Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing Facility
finance.yahoo.com - January 26 at 9:21 AM
Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing FacilityImprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility
finance.yahoo.com - January 24 at 9:43 AM
What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial StrengthWhat You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength
finance.yahoo.com - January 22 at 5:56 PM
NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)
finance.yahoo.com - January 15 at 11:04 AM
Head to Head Comparison: Imprimis Pharmaceuticals (IMMY) versus The CompetitionHead to Head Comparison: Imprimis Pharmaceuticals (IMMY) versus The Competition
www.americanbankingnews.com - January 11 at 11:16 PM
Head-To-Head Analysis: Imprimis Pharmaceuticals (IMMY) and Its PeersHead-To-Head Analysis: Imprimis Pharmaceuticals (IMMY) and Its Peers
www.americanbankingnews.com - January 11 at 3:34 PM
Reviewing Imprimis Pharmaceuticals (IMMY) and Its RivalsReviewing Imprimis Pharmaceuticals (IMMY) and Its Rivals
www.americanbankingnews.com - January 6 at 11:52 AM
Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?
finance.yahoo.com - January 4 at 3:43 PM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:21 PM
Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:24 PM
Head to Head Review: Imprimis Pharmaceuticals (IMMY) versus Its CompetitorsHead to Head Review: Imprimis Pharmaceuticals (IMMY) versus Its Competitors
www.americanbankingnews.com - December 23 at 7:24 PM
Critical Survey: Imprimis Pharmaceuticals (IMMY) vs. Its RivalsCritical Survey: Imprimis Pharmaceuticals (IMMY) vs. Its Rivals
www.americanbankingnews.com - December 16 at 11:28 AM
Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?
finance.yahoo.com - November 29 at 3:43 PM
Imprimis Pharmaceuticals Announces Third Quarter 2017 ResultsImprimis Pharmaceuticals Announces Third Quarter 2017 Results
finance.yahoo.com - November 15 at 2:55 AM
Investor Network Invites You to the Imprimis Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, November 14, 2017Investor Network Invites You to the Imprimis Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, November 14, 2017
finance.yahoo.com - November 13 at 7:54 PM
Short Interest in Imprimis Pharmaceuticals, Inc. (IMMY) Grows By 70.6%Short Interest in Imprimis Pharmaceuticals, Inc. (IMMY) Grows By 70.6%
www.americanbankingnews.com - November 13 at 3:34 AM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017
finance.yahoo.com - November 11 at 12:11 PM
Imprimis Pharmaceuticals, Inc. (IMMY) Set to Announce Earnings on MondayImprimis Pharmaceuticals, Inc. (IMMY) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 6 at 5:44 AM
Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. ESTImprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST
finance.yahoo.com - October 31 at 10:23 PM
Imprimis Launches Surface Pharmaceuticals SubsidiaryImprimis Launches Surface Pharmaceuticals Subsidiary
finance.yahoo.com - October 25 at 6:27 AM
What does Imprimis Pharmaceuticals Inc’s (IMMY) Balance Sheet Tell Us Abouts Its Future?What does Imprimis Pharmaceuticals Inc’s (IMMY) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - October 21 at 2:16 AM
Imprimis To Challenge Allergans Restasis With Cheaper ProductImprimis To Challenge Allergan's Restasis With Cheaper Product
seekingalpha.com - October 20 at 5:17 AM
Imprimis Pharmaceuticals (IMMY) Has Spiked To Nearly A 2-Month HighImprimis Pharmaceuticals (IMMY) Has Spiked To Nearly A 2-Month High
www.rttnews.com - October 20 at 5:17 AM
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®
finance.yahoo.com - October 20 at 12:13 AM
Imprimis Pharmaceuticals Inc (IMMY) Stock: Gaining On Generic Version of RestasisImprimis Pharmaceuticals Inc (IMMY) Stock: Gaining On Generic Version of Restasis
finance.yahoo.com - October 20 at 12:13 AM
Imprimis Pharma to take on Allergans Restasis with cheaper productImprimis Pharma to take on Allergan's Restasis with cheaper product
finance.yahoo.com - October 20 at 12:13 AM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 18 at 1:17 AM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 6, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 11:11 PM
What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?
finance.yahoo.com - October 5 at 9:50 PM

SEC Filings

Imprimis Pharmaceuticals (NASDAQ:IMMY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Imprimis Pharmaceuticals (NASDAQ:IMMY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Imprimis Pharmaceuticals (NASDAQ IMMY) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.